There is a large public health challenge posed by Alzheimer, Parkinson, Multiple Sclerosis, Huntington, Lou Gehrig and other neurodegenerative conditions that affect memory, movement and mood.
The establishment of a national Institutional Review Board for neurodegenerative disease (NIRB-ND) could significantly alter the therapy-development landscape by promoting more efficient and effective human subject safety and research. Currently, many geographically dispersed multi-center clinical trials for neurodegenerative diseases require participating sites to obtain separate institutional review board (IRB) approval. Often individual IRBs have differing guidelines for each site creating a heavy administrative burden and lengthened project timelines for study sponsors.
The National Biomedical Research Ethics Council aims to improve human subject safety as well as increase the efficiency and speed in the conduct of large-scale multi-center trials.
